Evidence map›Paper›PMID 27420633›Full record

ArticleCancer epidemiology2016

Associations of NSAID and paracetamol use with risk of primary liver cancer in the Clinical Practice Research Datalink.

Baiyu Yang, Jessica L Petrick, Jie Chen, Katrina Wilcox Hagberg, Vikrant V Sahasrabuddhe, Barry I Graubard, Susan Jick, Katherine A McGlynn

Open access · greenAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer epidemiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Baiyu YangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892-9774, USA. Electronic address: baiyu.yang@nih.gov.
Jessica L PetrickDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892-9774, USA.
Jie ChenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892-9774, USA.
Katrina Wilcox HagbergBoston Collaborative Drug Surveillance Program and Boston University School of Public Health, Lexington, MA, 02421, USA.
Vikrant V SahasrabuddheDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892-9774, USA; Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, 20892-9783, USA.
Barry I GraubardDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892-9774, USA.
Susan JickBoston Collaborative Drug Surveillance Program and Boston University School of Public Health, Lexington, MA, 02421, USA.
Katherine A McGlynnDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892-9774, USA.
Division of Cancer Epidemiology and GeneticsNational Cancer Institute · USBoston Collaborative Drug Surveillance Program · USBoston University · US

Funding

Studies of Rare CancersZIACP010158 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MCGLYNN, KATHERINE · 2009 to 2025
$19.1M
Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Liver cancer incidence has been rising rapidly in Western countries. Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol are widely-used analgesics that may modulate the risk of liver cancer, but population-based evidence is limited. We conducted a case-control study (1195 primary liver cancer cases and 4640 matched controls) within the United Kingdom's Clinical Practice Research Datalink to examine the association between the use of prescription NSAIDs and paracetamol and development of liver cancer. Multivariable-adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression. Overall, ever-use of NSAIDs was not associated with risk of liver cancer (aOR=1.05, 95% CI=0.88-1.24), regardless of recency and intensity of use. Use of paracetamol was associated with a slightly increased risk of liver cancer (aOR=1.18, 95% CI=1.00-1.39), particularly among individuals with body mass index<25kg/m(2) (aOR=1.56, 95% CI=1.17-2.09). Our results suggest that NSAID use was not associated with liver cancer risk in this population. Ever-use of paracetamol may be associated with slightly higher liver cancer risk, but results should be interpreted cautiously due to methodological limitations. Given that paracetamol is a widely-used analgesic, further examination of its relationship with liver cancer is warranted.

Indexed as

AcetaminophenAnti-Inflammatory Agents, Non-SteroidalCase-Control StudiesHumansLiver NeoplasmsOdds RatioRisk FactorsAcetaminophenAnti-Inflammatory Agents, Non-SteroidalAnalgesicsCase-control studyLiver cancerMedical records database

Identifiers

PMID27420633
PMCPMC5031234
OpenAlexW2460276087

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.